Consensus IntelGenx Technologies Corp. Toronto S.E.

Equities

IGX

US45822R1014

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2021-10-17 pm EDT			5-day change	1st Jan Change
0.78 ^CAD	+9.86%		+50.00%	+173.68%

Apr. 08	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
Apr. 05	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Evolution of the average Target Price on IntelGenx Technologies Corp.

Price target over the last 5 years

History of analyst recommendation changes

f33057ede3a96116faa30.FBk5_32kYlk_XprfjcVTkOvGYGg-kb2GMQnUg1r9gUg.Q1dpuTLrNRVUGcrr_KI__7izCiRXvMnvYE6jtBzO6wJTVWGoF5RUElot9Q~bea77e595e035b33425f3de31a3a881f

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.164

Average target price